A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 20, Issue 4, 2014, Pages 606-613

  Vahabnezhad, Elaheh ^a   Rabizadeh, Shervin ^b   Dubinsky, Marla C ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Anti infliximab antibody; Crohn's disease; Inflammatory bowel disease; Infliximab; Pediatric; Ulcerative colitis

Indexed keywords

ADALIMUMAB; ALBUMIN; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; NATALIZUMAB; ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT;

ABNORMAL LABORATORY RESULT; ADOLESCENT; ALBUMIN BLOOD LEVEL; ARTICLE; CHILD; CHILDHOOD DISEASE; COHORT ANALYSIS; COLON RESECTION; CORTICOSTEROID THERAPY; CROHN DISEASE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; PRIORITY JOURNAL; RECURRENT INFECTION; REMISSION; SCHOOL CHILD; SEIZURE; TERTIARY CARE CENTER; TREATMENT DURATION; ULCERATIVE COLITIS; ADULT; BLOOD; COLITIS, ULCERATIVE; DRUG COMBINATION; IMMUNOLOGY; MAINTENANCE CHEMOTHERAPY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; TIME; TREATMENT FAILURE; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAINTENANCE CHEMOTHERAPY; MALE; METHOTREXATE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TERTIARY CARE CENTERS; TIME FACTORS; TREATMENT FAILURE; YOUNG ADULT;

EID: 84898735318     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000003     Document Type: Article

References (24)

1. Benchimol EI, Guttmann A, Griffiths AM, et al. Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data. Gut. 2009;58:1490-1497.
2. Kugathasan S, Judd RH, Hoffmann RG, et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr. 2003; 143:525-531.
3. Baldassano RN, Piccoli DA. Inflammatory bowel disease in pediatric and adolescent patients. PCNA, Gastroenterol Clin North Am. 1999;28: 445-458. Review.
4. Hyams JS, Lerer T, Griffiths A, et al. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis. 2009;15:816-822.
5. Hyams JS, Lerer T, Griffiths A, et al. Outcome following infliximab therapy in children with ulcerative colitis. Am J Gastroenterol. 2010; 105:1430-1436.
6. Assa A, Hartman C, Weiss B, et al. Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease. J Crohns Colitis. 2013;7:369-376.
7. Hyams J, Walters TD, Crandall W, et al. Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension. Curr Med Res Opin. 2011;27: 651-662.
8. Gonzaga JE, Ananthakrishnan AN, Issa M, et al. Durability of infliximab in Crohn's disease: a single-center experience. Inflamm Bowel Dis. 2009; 15:1837-1843.
9. Lin KK, Velayos F, Fisher E, et al. Durability of infliximab dose intensification in Crohn's disease. Dig Dis Sci. 2012;57:1013-1019.
10. Chaparro M, Panes J, Garcia V, et al. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response. J Clin Gastroenterol. 2011;45:113-118.
11. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359: 1541-1549.
12. Vermeire S, Noman M, Van Assche G, et al. The effectiveness of concomitant immunosuppressive therapy to suppress formation of antibodies to infliximab in Crohn's disease. Gut. 2007;56:1226-1231.
13. Colombel JF, Sanborn WJ, Reinisch W, et al. Infliximab, azathioprine or combination therapy for Crohn's disease. N Engl J Med. 2010;362: 1383-1395.
14. Breedveld F, Weisman M, Kavanaugh A, et al. A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26-37.
15. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:265-267.
16. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1248-1254.
17. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003; 348:601-608.
18. Gidrewicz D, Lehman D, Rabizadeh S, et al. Primary EBV infection resulting in lymphoproliferative disease in a teenager with Crohn's disease. J Pediatr Gastroenterol Nutr. 2011;52:103-105.
19. Mozziconacci N, Vermeire S, Laharie D, et al. Efficacy of a third anti- TNF monoclonal antibody in Crohn's disease after a failure of two other anti-TNFs. Gastroenterology. 2008;134:A663.
20. Sandborn WJ, Hanauer S, Loftus EV Jr, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol. 2004;99:1984-1989.
21. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829-838.
22. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9: 36-41.
23. Rosh J, Gross T, Mamula P, et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease. A cautionary tale? Inflamm Bowel Dis. 2007;13:1024-1030.
24. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552-1563.